Early observations and pilot data that first suggested a new direction
Epinephrine has been the first-line treatment for anaphylaxis since the 1900s, but delivery method remained debated for decades. The IM vs SC administration debate was settled by Simons et al. in 2001, showing that IM injection into the anterolateral thigh achieved significantly higher and faster peak plasma epinephrine levels compared to SC injection or IM deltoid injection. Despite this evidence and the availability of auto-injectors (EpiPen approved 1987), studies consistently showed that epinephrine was underused in anaphylaxis, with only 20-30% of patients receiving it before arriving at the emergency department. Barriers included needle phobia, device complexity, fear of side effects, and failure to carry auto-injectors.
Landmark RCTs and pivotal trials that established the evidence base
Auto-injector technology evolved with multiple devices entering the market to address usability concerns. Comparative studies showed significant error rates across all devices, with up to 50% of patients unable to correctly demonstrate their auto-injector technique. Weight-based dosing studies established that the standard 0.3mg adult and 0.15mg pediatric doses were inadequate for many patients, particularly children in the 15-30kg range and obese adults. The recognition that epinephrine underuse was largely a delivery problem rather than a knowledge problem drove innovation toward needle-free alternatives. Pharmacokinetic studies in the 2010s began exploring intranasal, sublingual, and inhaled routes as potential needle-free delivery systems.
Follow-up studies, subgroup analyses, and real-world validation
Neffy (epinephrine nasal spray) developed by ARS Pharmaceuticals represented a breakthrough in needle-free epinephrine delivery. Phase 1 pharmacokinetic studies demonstrated that intranasal epinephrine achieved therapeutic plasma levels within minutes, comparable to IM auto-injector delivery. The pivotal EPIPHAST studies showed that while peak epinephrine levels were slightly lower than IM injection, the ease of administration and elimination of needle-related barriers could dramatically increase real-world epinephrine use. In a simulated anaphylaxis study, intranasal epinephrine was administered correctly by 99% of participants vs 90% for auto-injectors, and administration time was significantly faster. The FDA approved neffy (2mg intranasal spray) in August 2024 for emergency treatment of anaphylaxis.
Integration into clinical practice guidelines and recommendations
Current anaphylaxis guidelines from WAO, EAACI, and AAAAI/ACAAI continue to recommend IM epinephrine into the anterolateral thigh as first-line treatment for anaphylaxis. Following FDA approval of neffy, guidelines are being updated to include intranasal epinephrine as an alternative delivery route, particularly for patients with needle phobia or those unable to use auto-injectors. The emphasis remains on prompt administration, with guidelines stressing that delayed epinephrine is the primary risk factor for fatal anaphylaxis. Second-dose epinephrine recommendations have also been clarified, with guidelines now advising carrying two doses and administering a second dose if symptoms do not improve within 5-15 minutes.
WAO Anaphylaxis Guidance 2020 Update
Epinephrine IM is first-line for anaphylaxis; prompt administration is the single most important intervention; carry two doses
EAACI Anaphylaxis Guidelines Update
IM epinephrine remains first-line; intranasal epinephrine recognized as emerging alternative delivery route with potential to improve real-world administration rates
Now
Current standard of care and ongoing research directions
The approval of neffy (intranasal epinephrine) in 2024 marks the most significant advance in anaphylaxis emergency treatment in decades. Early real-world data suggests dramatically improved carrying rates and willingness to administer, particularly among school personnel and caregivers previously hesitant about needle-based devices. Research continues on sublingual epinephrine films and inhaled epinephrine formulations as additional needle-free options. The field is also exploring wearable epinephrine delivery systems that could automatically detect anaphylaxis and administer treatment. Ongoing debates include optimal dosing in obesity, the role of epinephrine in biphasic anaphylaxis prevention, and whether earlier and more aggressive epinephrine use could further reduce anaphylaxis mortality.
How does intranasal epinephrine compare to auto-injectors for anaphylaxis?+
Intranasal epinephrine (neffy) achieves therapeutic plasma levels within minutes, similar to IM auto-injectors. While peak levels may be slightly lower, the real-world advantages are significant: 99% correct administration rate (vs 90% for auto-injectors), faster delivery time, no needle-related barriers, and room temperature storage. The net clinical benefit may be superior due to improved real-world use.
Why is epinephrine so underused in anaphylaxis despite being the first-line treatment?+
Multiple barriers contribute: needle phobia (affects 20-30% of adults), device complexity (up to 50% incorrect technique), failure to carry devices, uncertainty about when to use it, fear of cardiac side effects, and device cost. Studies show only 20-30% of anaphylaxis patients receive epinephrine before reaching the ED. Needle-free formulations directly address the largest barrier.
Is the standard EpiPen dose appropriate for all patients?+
No. The standard 0.3mg adult dose may be insufficient for larger adults, and there is a dosing gap for children 15-30kg where neither the 0.15mg junior nor 0.3mg adult dose is optimal. Obese patients may also have inadequate needle penetration to muscle with standard-length needles. Weight-based dosing guidelines recommend 0.01mg/kg up to 0.5mg, but auto-injectors only come in fixed doses.
When should a second dose of epinephrine be given?+
Guidelines recommend a second dose if anaphylaxis symptoms do not improve or recur within 5-15 minutes of the first dose. Approximately 10-20% of anaphylaxis episodes require two or more doses. Biphasic reactions (recurrence after initial resolution) occur in 1-20% of cases, typically within 4-12 hours. All patients should carry at least two doses of epinephrine.
